Pharmacogenomics and the evolution of healthcare : is it time for cost-effectiveness analysis at the individual level?
- PMID: 15217306
- DOI: 10.2165/00019053-200422080-00002
Pharmacogenomics and the evolution of healthcare : is it time for cost-effectiveness analysis at the individual level?
Abstract
The efficacy and toxicity of any given drug can vary substantially from one individual to another. The heterogeneity in individual genetics contributes, in part, to this variability. Pharmacogenomics uses each patient's individual genetic information to identify the drug with the best efficacy-safety profile for that patient. However, heterogeneity is also present in individuals' preferences for alternate efficacy-safety profiles. We argue that as healthcare evolves towards individualised drug therapy, preference elicitation and cost-effectiveness analysis should also be performed at the individual level to maximise societal welfare.
Comment in
-
On pharmacogenomics and cost-effectiveness analysis at the individual level.Pharmacoeconomics. 2005;23(5):527. doi: 10.2165/00019053-200523050-00011. Pharmacoeconomics. 2005. PMID: 15896103 No abstract available.
Similar articles
-
Cost-effectiveness of genotyping to guide treatment.Pharmacogenomics. 2014 Apr;15(6):727-9. doi: 10.2217/pgs.14.24. Pharmacogenomics. 2014. PMID: 24897279 No abstract available.
-
An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics.Pharmacogenomics. 2003 May;4(3):231-9. doi: 10.1517/phgs.4.3.231.22691. Pharmacogenomics. 2003. PMID: 12718713 Review.
-
The role of cost-effectiveness analysis in the era of pharmacogenomics.Pharmacoeconomics. 2004;22(8):481-93. doi: 10.2165/00019053-200422080-00001. Pharmacoeconomics. 2004. PMID: 15217305 Review.
-
Cost-effectiveness analysis in pharmacogenomics.Pharmacogenomics. 2010 May;11(5):643-6. doi: 10.2217/pgs.10.45. Pharmacogenomics. 2010. PMID: 20415553 Review.
-
Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs.Pharmacogenomics. 2012 Sep;13(12):1405-17. doi: 10.2217/pgs.12.124. Pharmacogenomics. 2012. PMID: 22966889 Review.
Cited by
-
On pharmacogenomics and cost-effectiveness analysis at the individual level.Pharmacoeconomics. 2005;23(5):527. doi: 10.2165/00019053-200523050-00011. Pharmacoeconomics. 2005. PMID: 15896103 No abstract available.
-
Do pharmacogenomic tests provide value to policy makers?Pharmacoeconomics. 2006;24(12):1173-7. doi: 10.2165/00019053-200624120-00002. Pharmacoeconomics. 2006. PMID: 17129072 No abstract available.
-
Does pharmacogenomics provide an ethical challenge to the utilisation of cost-effectiveness analysis by public health systems?Pharmacoeconomics. 2005;23(5):445-7. doi: 10.2165/00019053-200523050-00004. Pharmacoeconomics. 2005. PMID: 15896096
-
Optimal assignment of treatments to health states using a Markov decision model: an introduction to basic concepts.Pharmacoeconomics. 2006;24(4):345-54. doi: 10.2165/00019053-200624040-00005. Pharmacoeconomics. 2006. PMID: 16605281
-
Acknowledging patient heterogeneity in economic evaluation : a systematic literature review.Pharmacoeconomics. 2013 Feb;31(2):111-23. doi: 10.1007/s40273-012-0015-4. Pharmacoeconomics. 2013. PMID: 23329430
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical